araag2/HINT huggingface dataset:
Clinical trial NCT01360554 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: dacomitinib (pf-00299804), active comparator (erlotinib), placebo erlotinib, placebo pf00299804
SMILES: COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Evidence of pathologically confirmed, advanced NSCLC (with known histology).

          -  Prior treatment with at least one and no more than two systemic therapy regimens (at
             least one must be standard chemotherapy for advanced NSCLC).

          -  Adequate tissue sample must be submitted prior to randomization for tumor biomarker
             analyses.

          -  Adequate renal, hematologic, liver function.

          -  ECOG PS of 0-2.

          -  Radiologically measurable disease.

        Exclusion Criteria:

          -  Small cell histology.

          -  Symptomatic brain mets or known leptomeningeal mets.

          -  Prior therapy with agent known or proposed to be active by action on EGFR tyrosine
             kinase or other HER family proteins.

          -  Uncontrolled medical disorders.
Clinical trial NCT00650104 (phase 3, status: completed)
Conditions: parkinson disease
ICD codes: G20
Drugs: ropinirole xl (formerly cr)
SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males or non-pregnant/non-breast feeding females

          -  At least 30 years of age

          -  Diagnosis of idiopathic Parkinson''s disease (Hoehn & Yahr criteria)

          -  Completed either Study 167 or Study 164

        Exclusion Criteria:

          -  Presence of uncontrolled psychiatric, hematological, renal, hepatic,endocrinological,
             neurological, cardiovascular disease or active malignancy

          -  Dizziness or fainting due to orthostatic hypotension on standing

          -  Significant sleep disorder

          -  Drug abuse or alcoholism
Clinical trial NCT01768286 (phase 3, status: completed)
Conditions: chronic hepatitis c virus
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 18, with chronic genotype 1 HCV infection

          -  HCV treatment-experienced, including patients who have previously failed a
             nonstructural protein (NS)3/4A protease inhibitor plus pegylated interferon (PEG)/RBV
             regimen

          -  HCV RNA > 10,000 IU/mL at screening

          -  Cirrhosis determination; a liver biopsy may be required

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Coinfection with HIV or hepatitis B virus

          -  Current or prior history of clinical hepatic decompensation

          -  Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin
             cancers)

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol
Clinical trial NCT00357097 (phase 3, status: completed)
Conditions: restless legs syndrome, moderate to severe idiopathic restless legs syndrome (rls)
ICD codes: G25.81, E20.0, I95.0, L50.1, D61.3, G24.2, G24.4, G60.3
Drugs: ropinirole
SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  diagnosis of idiopathic Restless Legs Syndrome, confirmed by a score of at least 11 on
             the RLS Diagnostic Index

          -  certain severity of symptoms (at least score of 15 on the International Restless Legs
             Score (IRLS)

          -  Have had RLS symptoms for at least 15 nights in the last four weeks.

          -  < 6 hours of sleep in nights with RLS symptoms

          -  MADRS (depression rating scale) score of at least 12 (= borderline to depression) at
             baseline

        Exclusion criteria:

          -  any other sleep disorder that might interfere with the RLS symptoms or sleep (e.g.
             sleep apnea disorder, narcolepsy)

          -  Secondary RLS due to diagnosis of renal insufficiency, polyneuropathy, pregnancy (see
             below), iron deficiency anemia

          -  Any significant psychiatric disorders (e.g. schizophrenia, bipolar disorder);
             depression which by judgement of the investigator is caused by RLS, is not an
             exclusion criterion.

          -  Current or past suicidality

          -  medication known to trigger/aggravate/ cause or interfere with RLS symptoms (e.g. most
             antidepressants, lithium, neuroleptics, opioids, carbidopa, clonidine, antihistamines,
             anticonvulsants etc.).

          -  daytime RLS symptoms which require treatment (daytime: 10 a.m. until 6 p.m.).

          -  concomitant movement disorders (e.g. Parkinson's Disease, dyskinesia, dystonia).

          -  medical conditions with symptoms which could affect assessments of efficacy (e.g.
             diabetes, rheumatoid arthritis, fibromyalgia syndrome, cancer etc.).

          -  Subjects taking any medication known to induce drowsiness or to affect sleep.

          -  Subjects who are pregnant, lactating or of childbearing potential. Women of
             childbearing potential must use adequate contraception

          -  clinically significant or unstable medical conditions (e.g. severe heart disease,
             severe liver or kidney disease etc.).

          -  pain syndromes, caused by other disorders than RLS

          -  excessive caffeine intake

          -  diastolic blood pressure >110mmHg or <50mmHg or systolic blood pressure >180mmHg or
             <90mmHg at baseline.

          -  Withdrawal, introduction, or change in dose of hormone replacement therapy (HRT) or
             the oral contraceptive pill (OCP) and/or certain drugs which are known to interact
             with ropinirole (e.g. ciprofloxacin, cimetidine, tobacco, omeprazole).
Clinical trial NCT01560195 (phase 3, status: unknown status)
Conditions: nsclc, neutropenia, febrile neutropenia
ICD codes: D70.4, D70.8, D70.9, P61.5, D70.3
Drugs: pegylated rhg-csf: 100µg/kg, pegylated rhg-csf: 6mg, placebo and rhg-csf 5ug/kg/d
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Investigator diagnosis of staged III or IV NSCLC

          -  Age 18 to 70 years

          -  ECOG performance status ≤ 1

          -  Chemotherapy naïve

          -  Body weight ≥ 45kg

          -  Hemoglobin ≥ 100g/L; white blood cell ≥ 4.0×109/L; absolute neutrophil count ≥1.5 ×
             109/L; platelet count ≥ 100 × 109/L

          -  Alanine transarninase ≤1.5×ULN; aspartate aminotransferase ≤1.5×ULN; serum creatinine
             ≤1.5×ULN; total bilirubin ≤1.5×ULN

        Exclusion Criteria:

          -  History of systematic chemotherapy or radical radiation therapy

          -  Prior bone marrow or stem cell transplantation

          -  Received systemic antibiotics treatment within 72 h of chemotherapy

          -  Pregnancy or lactation
Clinical trial NCT01170442 (phase 3, status: terminated)
Conditions: diabetes mellitus, vitamin d deficiency
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9, E55.9, D51.0, D51.1, D51.3, D51.8, D51.9, E50.0
Drugs: vitamin d3 2000 iu, vitamin d3 5000 iu, placebo
SMILES: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    in adequate enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Type II diabetics living in Riyadh area who consume no more than one serving of
             milk/day

          -  Do not take vitamin supplement

          -  Habitually have less than 10 hour of sun exposure per week

          -  Don't suffer from granulomatous conditions, liver disease, or kidney disease

          -  Don't take anticonvulsants, barbiturates, or steroids.

          -  Stable glycemic control (not more than 0.5% difference between current HA1c and a HA1c
             obtained 2-4 months earlier)

          -  Current HA1c between 6.5 and 8%, and current total 25 OH vitamin D level between 10-30
             nmol/L.
Clinical trial NCT00660387 (phase 3, status: completed)
Conditions: advanced parkinson's disease
ICD codes: G20
Drugs: levodopa carbidopa intestinal gel (lcig), placebo gel, levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets, placebo (pbo) oral capsules
SMILES: C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, [H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease
             Society (UKPDS) Brain Bank Criteria

          -  Levodopa-responsive participants who demonstrate some identifiable 'on response,'
             established by Investigator observation

          -  Demonstrate severe motor fluctuations in spite of individually optimized treatment and
             where therapy options are indicated

        Exclusion Criteria:

          -  Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as
             secondary parkinsonism

          -  Undergone surgery for the treatment of PD

          -  Contraindications to levodopa

          -  Subjects with any neurological deficit that may interfere with the study assessments
Clinical trial NCT00200967 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: salmeterol, beclomethasone hfa
SMILES: OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, ages 18 and older

          -  Clinical history consistent with asthma

          -  For subjects regularly using inhaled corticosteroids, FEV1 50% of predicted,
             methacholine PC20 FEV1 16 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs
             of inhaled albuterol

          -  For subjects not regularly using inhaled corticosteroids, FEV1 40% of predicted,
             methacholine PC20 FEV1 8 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs of
             inhaled albuterol

          -  Genotype eligibility (determined during screening)

        Exclusion Criteria:

          -  Smoker (total smoking history must be less than 10 pack years)

          -  Significant unstable medical condition other than asthma

          -  History of life-threatening asthma requiring treatment with intubation and mechanical
             ventilation in the past 10 years

          -  Pregnant or lactating
Clinical trial NCT03662763 (phase 3, status: completed)
Conditions: attention deficit disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: extended-release guanfacine hydrochloride (spd503), placebo oral capsule
SMILES: NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  male or female, aged 6-17 years at the time of consent/assent at Screening/Visit 1

          -  subject meets DSM-IV-TR criteria for primaru diagnosis of ADHD

          -  subject has a minimum ADHD-RS-IV total score of 32 at enrolment/visit 2

          -  subject has a minimum CGI-S score of 4 at Enrolment/Visit 2

          -  subject is able to swallow intact tablets

        Exclusion Criteria:

          -  subject has a current controlled or uncontrolled, co-morbid psychiatric diagnosis.

          -  subject has a know history or presence of structural cardiac abnormalities

          -  subject with orthostatic hyupotension or a known history of controlled or uncontrolled
             hypertension

          -  current use of any prohibited medication or other medications, including herbal
             supplements that affet blood pressure, or heart rate or that have CNS effects or
             affect cognitive performance

          -  subject is significant overweight based on Centre for disease control and prevention
             BMI for age gender specific charts. Significantly overweight is defined as a BMI >95
             th percentile Children aged 6-12 years with a body weight ,25,0kg, or adolescents aged
             13-17 years with a body weight <43 kg or >91 kg at screening/visit 1

          -  subject is currently considered a suicide risk in the opinion of the investigator

          -  history of failure to respond to an adequate trial of an alfa2-agonist for the
             treatment of ADHD.
Clinical trial NCT00395018 (phase 3, status: completed)
Conditions: hepatitis b, chronic
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: entecavir
SMILES: CCOC(=O)C1=CC=C(N)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients receiving orthotopic liver transplant (OLT) due to end-stage liver disease
             because of chronic HBV infection, with HBV-DNA < 172 IU/mL (approximately < 1000
             copies/mL) prior to liver transplant

          -  Must have detectable hepatitis B surface antigen (HBsAg) at screening and for at least
             24 weeks prior to screening

        Exclusion Criteria:

          -  Patients with hepatocellular carcinoma with evidence of extrahepatic spread, multiple
             tumors ≥ 6.5 cm in diameter or there is up to three nodules ≥ 4.5 cm in diameter and
             total tumor diameter is ≥ 8 cm

          -  Co-infection with human immunodeficiency virus (HIV), cytomegalovirus (CMV),
             Epstein-Barr virus (EBV) or hepatitis C virus (HCV)
Clinical trial NCT00493974 (phase 3, status: terminated)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: zileuton, placebo
SMILES: CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of feasibility due to low recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Admitted to the hospital for a COPD exacerbation

          -  FEV1 less than 60% of predicted level

          -  At least 10 pack years of smoking

        Exclusion Criteria:

          -  Any uncontrolled systemic disease

          -  Known hypersensitivity to zileuton

          -  Asthma

          -  Lobar pneumonia or pulmonary edema

          -  Interstitial lung disease

          -  Medical condition that is likely to limit survival to less than 30 days at the time of
             study entry

          -  History of liver disease

          -  Current use of theophylline

          -  Participation in another clinical trial in the COPD Clinical Research Network

          -  Incarceration

          -  Institutionalization

          -  Pregnant

          -  History of a suicide attempt

          -  Prior inpatient admission for a psychiatric disorder

          -  Bipolar disorder

        '
Clinical trial NCT01299376 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: l50/h12.5/a5, l50/h12.5, placebo to l50/h12.5/a5, placebo to l50/h12.5
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Participant has a diagnosis of essential hypertension

          -  Participant is being treated with a single, or dual combination treatment for
             hypertension and will be able to discontinue the prior antihypertensive medication

          -  Participant has a mean trough SiDBP of ≥ 90 mmHg and < 110 mmHg

          -  Participant has a mean trough SiSBP of ≥ 140 mmHg and < 200 mmHg

          -  Participant has no clinically significant abnormality at screening visit

        Exclusion criteria:

          -  Participant is currently taking >2 antihypertensive medications

          -  Participant has a history of significant multiple and/or severe allergies to
             ingredients of Nu-Lotan or Preminent, amlodipine or dihydropyridine drug and thiazide
             drug or related drug (i.e., sulfonamide-containing "chlortalidone" medicines)

          -  Participant is, at the time of signing informed consent, a user of recreational or
             illicit drugs or has had a recent history within the last year of drug or alcohol
             abuse or dependence

          -  Participant is pregnant or breastfeeding, or expecting to conceive OR the pregnancy
             test is positive at screening visit (Visit 1)

          -  Participant is currently participating or has participated in a study with an
             investigational compound or device within 30 days of signing informed consent
Clinical trial NCT00541021 (phase 3, status: unknown status)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine hydrochloride, sorafenib tosylate
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Diagnosis of adenocarcinoma of the pancreas

               -  Locally advanced or metastatic disease

          -  Measurable disease, defined as at least 1 lesion measurable by RECIST criteria

        Exclusion criteria:

          -  Brain metastases

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  WHO performance status 0-2

          -  Absolute neutrophil count > 1,500/mm^3

          -  Platelet count > 100,000/mm^3

          -  Creatinine < 1.5 times normal

          -  Transaminases < 2 times normal (5 times normal if liver metastases)

          -  Total bilirubin < 1.5 times normal

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  Pregnant or nursing

          -  Intestinal occlusion

          -  Prior inflammatory intestinal disease

          -  Crohn's disease

          -  Hemorrhagic rectal colitis

          -  Peripheral neuropathy > grade 2

          -  Other severe illness, including any of the following:

               -  Unstable cardiac disease, even if treated

               -  Psychological or neurological disease including dementia

               -  Uncontrolled active infection

               -  Other severe illness that would compromise study participation

          -  Impossible to receive study therapy due to geographical, social, or psychological
             reasons

          -  Other malignancy within the past 5 years except basal cell skin cancer or carcinoma in
             situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Inclusion criteria:

          -  See Disease Characteristics

          -  At least 6 months since prior chemotherapy or radiochemotherapy

          -  At least 4 weeks since prior radiotherapy and/or surgery

        Exclusion criteria:

          -  Prior therapy for advanced disease

          -  Prior inhibitors of kinase signaling (e.g., ras/raf, MEK, AKT, mTOR, or farnesyl
             transferase)

          -  Prior inhibitors of angiogenesis (e.g., bevacizumab)

          -  Prior organ graft or allogeneic transplantation

          -  Prior extensive intestinal resection

          -  Concurrent participation in another therapeutic study

          -  Concurrent inductors of CYP3A4 (e.g., barbiturates, anti-epileptics, or rifampicin)
Clinical trial NCT01261611 (phase 3, status: completed)
Conditions: cervical dystonia
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Dystonia with at least 18 months duration since onset.

          -  Previously untreated with Botulinum toxin-A (BTX-A) or -B or a minimum of 14 weeks
             since the last injection.

          -  TWSTRS score at baseline of: Total score ≥ 30, Severity Sub-Scale score ≥ 15,
             Disability Sub-Scale score ≥ 3, Pain Sub-Scale score ≥ 2.

        Exclusion Criteria:

          -  Known hypersensitivity to Botulinum toxin (BTX) or related compounds or any component
             in the study drug formulation (including cow milk protein).

          -  Pure anterocollis or pure retrocollis.

          -  In apparent remission from Cervical Dystonia.

          -  Known clinically significant underlying swallowing or respiratory abnormality which
             might be exacerbated by BTX treatment.

          -  Previous poor response to BTX treatment or known presence of BTX neutralising
             antibodies.

          -  Previous phenol or alcohol injections into the neck muscles.

          -  Previous myotomy or denervation surgery involving the neck or shoulder region.
Clinical trial NCT00714688 (phase 3, status: completed)
Conditions: attention deficit/ hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: prolonged release (pr) oros methylphenidate 54 mg, prolonged release (pr) oros methylphenidate 72 mg, placebo
SMILES: [H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1, [H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental
             Diseases, Fourth Edition (DSM-IV) and confirmed by the Conners' Adult ADHD Diagnostic
             Interview for DSM IV

          -  Described chronic course of ADHD symptomatology from childhood to adulthood, with some
             symptoms present before age 7 years and continue to meet DSM-IV criteria at the time
             of assessment

          -  CAARS score of at least or equal to 24 as determined by investigator at screening
             visit

          -  Patient agrees to take only the supplied study drug as treatment for ADHD during the
             study

          -  Patient agrees not to initiate a new behavioral modification program during the study
             or if currently using a behavioral modification program agrees not to change this
             program during the study.

        Exclusion Criteria:

          -  Known to be a non-responder to methylphenidate, or patient has a child known to be a
             non-responder to methylphenidate

          -  Has been treated with any methylphenidate-containing medication within 1 month of
             screening visit

          -  Participation in and premature withdrawal from 42603ATT3002, CR002479 or 42603ATT3004,
             CR011068 study

          -  Known allergy or hypersensitivity to methylphenidate, or components of PR OROS
             methylphenidate

          -  Any clinically unstable psychiatric condition including, but not limited to the
             following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder
             (OCD), anti-social personality disorder, borderline personality disorder.